NDAIRRIGATIONSOLUTIONPriority Review
Approved
Oct 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
RENACIDIN (citric acid, gluconolactone and magnesium carbonate) by United Therapeutics is acidifying activity [moa]. First approved in 1990.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENACIDIN is a urologic irrigation solution containing citric acid, gluconolactone, and magnesium carbonate that works through acidifying activity to dissolve calculi (kidney stones and other urinary tract deposits). Administered via irrigation route, it is indicated for patients with recurrent or residual calculi who require non-invasive dissolution therapy. The product represents a specialized, niche therapeutic approach to calculus management in urology.
$0.003BPart D
LOE ApproachingWith only $3M in annual Part D spending and approaching loss of exclusivity, the RENACIDIN brand team is likely small and focused on defending market position in a narrow urology segment.
Mechanism of Action
Acidifying Activity
Pharmacologic Class:
Calculi Dissolution Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENACIDIN shows zero linked job openings, indicating a minimal or inactive brand team at United Therapeutics. Career opportunities on this product are likely limited to small pockets of medical affairs or field-based urology specialists.
Company
Worked on RENACIDIN at United Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.